Melanoma Clinical Trials in California

Showing 61-79 of 79 trials

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

NCT00533702

The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine.

Metastatic Malignant Melanoma

Eli Lilly and Company106 participantsStarted Nov 2007

Decatur, Alabama, United States • Scottsdale, Arizona, United States • Scottsdale, Arizona, United States +14 more locations

COMPLETEDPHASE363 miles

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

NCT00257205

This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)

Melanoma

AstraZeneca655 participantsStarted Mar 2006

Huntsville, Alabama, United States • Mobile, Alabama, United States • Scottsdale, Arizona, United States +140 more locations

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Melanoma Trials in Other Cities

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

CCI-779 in Treating Patients With Metastatic Melanoma

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Phase II, 2nd Line Melanoma - RAND Monotherapy

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

Study of CP-675,206 in Refractory Melanoma

Vaccine Therapy for Patients With Stage IV Melanoma

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Other Conditions in California